%0 Journal Article
%T Current Status for Oral Platinum (IV) Anticancer Drug Development
%A Qian Mi
%A Shunshun Shu
%A Caixia Yang
%A Chuan Gao
%A Xian Zhang
%A Xiao Luo
%A Chonghuan Bao
%A Xia Zhang
%A Jun Niu
%J International Journal of Medical Physics,Clinical Engineering and Radiation Oncology
%P 231-247
%@ 2168-5444
%D 2018
%I Scientific Research Publishing
%R 10.4236/ijmpcero.2018.72020
%X Platinum-based
chemotherapeutic drugs such as cisplatin, carboplatin and oxaliplatin are
widely applied for the treatment of various types of tumors. However, poor
solubility, serious side effects, and more importantly, the intrinsic and
acquired resistance limit their clinical applications. These factors motivate
scientists to design and synthesize novel and more potent analogues lacking
disadvantages of clinical platinum drugs. Platinum (IV) complexes are one of
representatives. In this review, we summarized the investigations undertaken
into Platinum (IV) antitumor compounds since Rosenberg first noted their
antitumor activity. The synthesis method and mechanism of action of Platinum
(IV) complexes are outlined, as well as their chemical and pharmacological
properties. Recent advances in Platinum (IV) anticancer agents that have been
in clinical trials and photoactivatable Platinum (IV) complexes are also
summarized, and the purpose here is to provide insight into the requirements
for the antitumor activity of Platinum (IV) complexes and a basis for
progressing in a new platinum compound.
%K Platinum (IV) Complexes
%K Properties
%K Mechanism
%K Antitumor Activity
%K Cancer Therapy
%K Photoactivatable
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=84900